100,000, which is about 3 times the frequency they estimated for early-onset dystonia in non-Jews. 8 The authors calculated that the mutation in the Ashkenazi Jewish population first occurred in the northern part of the historic Jewish Pale (Lithuania, Byelorussia) 350 years ago. 8 All cases among the Ashkenazi Jews originally evaluated by Ozelius et al 1 had the same founder mutation based on several markers around the GAG deletion. Since then, however, a few other founders have been recognized as being responsible for the disease in single families, suggesting that there had been some recent spontaneous mutations. 2 The GAG deletion was estimated to account for about 90% of Ashkenazi Jewish patients who developed dystonia in the limbs at an early age. 10 Several studies that have appeared during the last few years have indicated that the range of DYT1 expression is limited. 11 The DYT1 phenotype is characterized by symptom onset in early age (ie, before 24 years). The limbs are affected in most cases, and the arms in 95% of cases. One of the limbs is affected first in 90% of cases, but the dystonia spreads to other parts of the body over time. There is some evidence that dystonia among Ashkenazi Jews tends to begin on the dominant side. 11 The cranial muscles are less likely to be involved. The phenotype produced by GAG deletion is similar in both the Ashkenazi Jewish and non-Jewish populations. 9 The clinical course of the disease among the 30 to 40% symptomatic cases is highly variable, extending from a mild focal disease to a generalized form with severe motor disability but without any other neurologic disturbances. Clinical features such as age of onset, site of onset, and distribution of symptoms 12 have prognostic significance. 10, 13, 14 Few studies describe the course of the disease in large groups of genetically confirmed patients with Oppenheim's dystonia who undergo therapeutic approaches (drugs and surgery) that have emerged over recent years. The most extensive investigation on Oppenheim's dystonia was done by Bressman et al on a group of patients with a mutation in the DYT1 gene (267 patients, 168 Ashkenazi Jews and 99 non-Jews). 10 This study did not, however, correlate the clinical course with the different therapeutic modalities that are now available for Oppenheim's dystonia. There are two recent reports on the therapeutic options in dystonia: one described the clinical course of five patients with Oppenheim's dystonia, 15 and the other is an overview of therapies but with- Continued next page out statistical applications of their effect on the patients' clinical course. 16 There are also isolated case reports on the outcome of surgical intervention, with 8 years of follow-up for thalamotomy 17, 18 but only 1 to 2 years of follow-up after pallidotomy with mixed results. [19] [20] [21] [22] [23] [24] Notably, very few patients were evaluated by validated and standardized scales, which makes it difficult to compare the published results.
We describe the clinical characteristics of genetically confirmed patients with Oppenheim's dystonia in Israel and the effect of modern therapeutic strategies on their disease course and quality of life. We believe that this information is of special importance for application in genetic counseling for addressing the issue of whether to terminate a pregnancy when the fetus has been identified as a carrier of the mutation.
SUBJECTS AND METHOD
All study participants were of Ashkenazi Jewish origin and all carried the GAG deletion in the DYT1 gene. We had confirmed at least two founders in earlier studies, according to the commonly used markers around this gene. 2 A neurologist trained in movement disorders examined all of the patients on study entry, and their medical history was compiled by detailed interviews with them and their relatives as well as from data retrieved from their records at the Movement Disorders Unit and documents from other hospitals as well as other outpatients clinics. The clinical assessment was based on an updated Dystonia Rating Scale and the Disability Scale. 25 
RESULTS

Patients' Characteristics and Age at Disease Onset
The study cohort was composed of 33 patients with Oppenheim's dystonia (19 male and 14 female, mean ± SD for age 27.8 ± 15.2 years, range 11-63), all residents of Israel. Twenty-five patients who had a positive family history of Oppenheim's dystonia originated from 10 families: their mean age at symptom onset was 10.7 ± 4.6 years (range 6.5-28), and their mean disease duration was 15.5 ± 13.8 years (range 3-54). The other 8 cases were sporadic: their mean age at symptom onset was 8.8 ± 1.6 years (range 6.5-11) ( Table 1) . 
Initial Symptoms
The first symptom of Oppenheim's dystonia was in the limbs in 32 patients, 28 of them in one limb. Twelve patients (37.5%) noticed the first dystonic symptom in the right arm, 9 (28%) patients in the right leg, 6 (19%) in the left leg, and 1 (3%) in the left arm. Two patients experienced the first dystonic spasms in both legs, one patient noticed symptoms in the right arm and neck simultaneously (segmental), and another patient had multifocal onset of the disease. One patient had only axial symptoms at disease onset (see Table  1 ). There was a strong tendency to develop initial symptoms on the dominant side of the body (72%), particularly in the dominant arm. Only seven patients (21%) developed the initial symptom on the nondominant side.
Patients who experienced the initial symptom in the lower limbs had a statistically significant (P < .05) earlier age at symptom onset (mean 8.7 ± 2.8 years) compared with those whose first symptom was in the upper limbs (mean 12.4 ± 3.7 years). There was a tendency for patients who developed the first symptom in the nondominant side to be younger (mean 8.1 ± 3.0 years) than those with initial symptoms on the dominant side (mean 11.1 ± 4.5 years), but this difference was not statistically significant. We observed a trend toward a significant association between earlier age of symptom onset and the appearance of symptoms on the nondominant leg (P < .10).
Disease Evolution and Duration
Twenty-one patients (63.6%) with a mean disease duration of 17.4 ± 15.7 years evolved to generalized dystonia. The generalization occurred over a period ranging between 6 months (7 cases) and 12 years (1 case), whereas 10 patients (48%) progressed to the generalized form within ~2 years from symptom onset. Five patients (15% of all patients and 25% of the ones with the generalized form) required a wheelchair 2 to 8 years after the onset of their symptoms (two of them regained the ability to walk after they successfully underwent a recent bilateral pallidotomy), and three patients (9%) started using walking aids 10 to 20 years after symptom onset.
Seven patients (21%) progressed to a multifocal form. The mean disease duration in this group was 18.6 ± 10.6 years. Five patients (15%) with a mean age of 23.4 ± 12 years remained with a focal dystonia. However, all five had symptoms for 4 years or less, suggesting that they might progress in the future. Notably, all but 1 of the 12 patients with a focal or multifocal form of dystonia (relatively benign course) developed the first symptom on the dominant side.
For dystonia distribution according to symptoms duration, see Table 2 .
Five patients (15%, 4 male) developed craniocervical dystonia; in two cases, it was the initial symptom and in three it began 4 to 15 years after symptom onset. Three of these five patients also developed spastic dysphonia as a late symptom, which appeared 4 to 15 years after symptom onset.
The mean Dystonia Rating Scale score that was obtained for the study cohort as a whole was 22.7 ± 14.7 (range 5-65). We observed a trend toward higher Dystonia Rating Scale scores with longer disease duration and earlier age of symptom onset. The mean group Disability Scale score was 7.7 ± 4.2 (range 2-17), and, as expected, it was higher in patients with generalized disease.
At least 3 years of a stable disease course were recorded in 14 patients (42%), 7 with generalized dystonia, 3 with the focal form, and the other 4 with a multifocal form. A stable course was associated in all cases with a current age of over 25 years (range 25-63 years) and more than 12 years of symptom duration (in 11 cases).
Cognitive functions were preserved in all patients and at all stages of the disease.
Treatment Modalities
The study patients were treated with different drug regimens and neurosurgical approaches. The medication used most often was baclofen (19 patients, 57.6%) at a maximum dose of 165 mg/day and a mean dose of 105 mg/day. The second most commonly used drug was trihexyphenidyl (17 patients, 51.5%) at a maximum dose of 120 mg/day and a mean dose of 30 mg/day. At the last follow-up, 15 patients (all with a generalized form) were being treated with baclofen, 9 as monotherapy and 6 in combination with trihexyphenidyl, with good tolerability and prolonged benefit.
Baclofen therapy improved leg dystonia and gait in 14 patients in dosages over 50 mg/day, and 9 of them enjoyed stable and prolonged benefit. The use of anticholinergic drugs, even when they were effective (6 patients), was limited by the secondary side effects. One child developed acute urinary retention on a regimen of 100 mg trihexyphenidyl. Drugs were discontinued only if significant side effects appeared. In general, most of the patients tended to taper anticholinergic drug intake over time with little or no worsening of the dystonia.
Twelve patients (36.4%) were treated for focal symptoms with botulinum toxin. All of them enjoyed periods of improvement, but only a few patients are on continuous botulinum toxin treatment, either because of loss of response or lack of efficacy.
Nine patients underwent neurosurgical stereotactic procedures: five underwent thalamotomy more than 10 years ago (two had a bilateral procedure) and four underwent pallidotomy in Toronto, Ontario, Canada (three had a bilateral procedure). Improvement was immediate and significant.
The follow-up period after thalamotomy ranged between 10 and 37 years. Retrospectively, the patients recalled an 328 Journal of Child Neurology / Volume 18, Number 5, May 2003 improvement period lasting from 1 month to 7 years, followed by further disease worsening afterward. All operated patients had the subjective impression that the disease progressed at a slower rate postoperatively, but this could not be objectively confirmed. The follow-up period after bilateral pallidotomy ranged from 2 to 4 years. The motor improvement was dramatic and significant during the first 3 to 4 months. However, there was a significant slowly progressive worsening of the motor state in most patients after the first year (Table 3) , as well as a late onset (more than 1 year postoperatively) of severe aphonia in one patient.
Of the nine patients who could not walk at the time of surgery, seven (77%) regained ambulation, two with and five without walking aids. The other two patients remained confined to a wheelchair.
DISCUSSION
Oppenheim's dystonia in Israel has the same classic features as those described in the literature. There is a slight male predominance, and the age at symptom onset varies but is generally around the second decade of life. The first appearance of symptoms in the limbs is almost equal for the upper and lower ones. The trend for an onset of the disease to occur in the arm in DYT1 Ashkenazi Jews was noticed first by Almasy et al 13 and is cited in the last guidelines for DYT1 phenotype diagnostic features. 10
Age at Onset and Presenting Symptom
It was our impression that an initial symptom in the dominant limb, mostly the arm, was associated with a milder course of the disease. An initial symptom in the lower nondominant limb tended to be associated with a younger age at disease onset and a more severe course, possibilities that have been suggested by others as well. 13, 26 Based on these results and on clinical impressions, the onset or severity of Oppenheim's dystonia may not be related to overactivity of the limb, as proposed by Byl et al. 27 
Natural History of Oppenheim's Dystonia and Its Relationship to the Treatment
We observed a tendency for stabilization of the clinical course after the age of 25 years, without any direct relationship to therapeutic modalities. A similar observation was also reported among a more heterogeneous group of dystonic patients in Israel by Inzelberg et al, 26 who observed a tendency for disease stabilization after 10 years. Greene had suggested that earlier treatment could slow down the disease progression, 28 but we could not test that hypothesis in the present study group, and a prospective controlled trial would be needed to do so.
Similar to the retrospective study by Greene, who described gait improvement in 30% of children with idiopathic dystonia treated with high-dose baclofen, 28 we also had the impression of a positive effect of baclofen on the lower limb-associated gait difficulties. However, because this is a retrospective data analysis report, we could not demonstrate this effect with the necessary objective measures and prospective data.
Our patients also exhibited the beneficial effect of anticholinergic drugs described in 61% pediatric and 38% adult patients by Fahn in 1983. 29 Because of the beneficial effects of baclofen and the side effects most patients experienced with trihexyphenidyl (even if the dose was increased extremely slowly), we did not test the reported effect of trihexyphenidyl in very high dosages. The current therapeutic modalities, baclofen (orally or intrathecally) and functional neurosurgery, have made very high-dose trihexyphenidyl a less common therapeutic strategy. Based on our and others' observations, we propose a practical therapeutic strategy using high-dose baclofen as first-line therapy. Anticholinergic drugs should be added in those cases when clinical benefit is not satisfied.
The ablative surgical procedures seem to give some transient benefit, depending on individual features and type of intervention. We looked for a relationship between the treatment modality and the dynamic course of the disease status during the last 4 years: 44% of the patients in the neurosurgically operated group (thalamotomy or pallidotomy, n = 9) have been clinically stable for 2 years and 67% are walking independently. This group of patients obviously includes the most disabled patients, and these outcomes are important as overall prognostic data for patients with severe Oppenheim's dystonia.
The long-term outcome after thalamotomy was described as being modest by Cardoso et al 24 when only 6 of 17 patients with severe primary dystonia maintained their postoperative improvement for a mean period of 32 months. The previous larger series by Cooper 17 and Tasker et al 18 reported a follow-up of 8 years with 25% good but transient improvement, but also 20% worsening or complications. 18 The follow-up period for our 6 patients who underwent thalamotomy was 37 years, but the maximum benefit lasted only 7 years.
The clinical course following bilateral posteroventral pallidotomy is of greater significance. Lin at al reported a follow-up of 6 to 12 months after bilateral pallidotomy in 18 patients and observed a partial improvement limited to the craniocervical region that was maintained for 1 year. 19 Teive et al reported 4 patients with idiopathic dystonia whose con- dition clearly improved at a follow-up of 180 days post-bilateral pallidotomy. 20 Others have also reported single or a few cases with good short-term outcome, but no study with long-term follow-up has been published thus far. [21] [22] [23] Our experience and that of others is that bilateral pallidotomy has significant short-term benefit in most cases. However, we observed a clear tendency for rapid and continuous worsening after the first postoperative year (a rate of 23 to 67% deterioration on the disability scales from year to year). Hypophonia has been recognized as a complication of pallidotomy since the 1998 study of Favre et al. 30 The appearance of a delay in the onset of severe postoperative hypophonia is worrying because we failed to detect hypophonia in any of our DYT1 patients who were not operated on. The fact that it developed several months to a year after surgery might suggest the presence of secondary changes in the thalamus, which developed slowly over time. Finally, in light of the recent reports about the benefit of globus pallidum interna (Gpi) stimulators, 31 one should hesitate lesion the globus pallidum interna in dystonic patients.
CONCLUSION
The findings of the current study provide data that can be used as guidelines for genetic counseling when a pregnancy involves a fetus that carries the GAG deletion in the DYT1 gene: (1) disease penetration is low (30-40%); (2) 63% of affected individuals progress to the generalized form and the rest will have a milder form (which, in most cases, will not require medical treatment); (3) most (75%) patients with the generalized form can maintain ambulation and independence with medications and/or surgery; and (4) modern treatment modalities provide even the most severe cases with a good chance for improvement and ambulation.
